SERPINA3 (Serpin Family A Member 3), also known as alpha-1 antichymotrypsin (ACT), is a serine protease inhibitor that plays critical roles in acute phase inflammation, protease regulation, and increasingly recognized functions in the nervous system. Originally characterized as an acute-phase reactant in peripheral inflammation, SERPINA3 has emerged as a significant player in Alzheimer's disease pathogenesis, neuroinflammation, and protein aggregation disorders.
| SERPINA3 Gene |
|---|
| Gene Symbol | SERPINA3 |
| Protein Name | Alpha-1 Antichymotrypsin (ACT) |
| Full Name | Serpin Family A Member 3 |
| Chromosomal Location | 14q32.13 |
| NCBI Gene ID | [12](https://www.ncbi.nlm.nih.gov/gene/12) |
| OMIM | [107450](https://www.omim.org/entry/107450) |
| UniProt | [P01011](https://www.uniprot.org/uniprot/P01011) |
| Protein Size | 418 amino acids, ~47 kDa |
| Expression | Brain (astrocytes), liver, lung, immune cells |
| Associated Diseases | [Alzheimer's](/diseases/alzheimer-disease), [Neuroinflammation](/diseases/neuroinflammation), COPD |
¶ Structure and Mechanism
SERPINA3 is a member of the serpin (serine protease inhibitor) superfamily. The serpin mechanism is unique among protease inhibitors:
- Conformational change: SERPINA3 undergoes a dramatic structural rearrangement upon binding to target proteases
- Irreversible inhibition: Forms a covalent complex with the protease that is effectively irreversible
- Target specificity: Primarily inhibits chymotrypsin-like proteases including:
- Cathepsin G
- Mast cell chymase
- Neutrophil elastase (minor)
The protein consists of:
- N-terminal signal peptide: Secretory pathway targeting
- Serpin domain: The characteristic serpin fold with reactive center loop (RCL)
- Heparin-binding domain: Enables interaction with glycosaminoglycans
SERPINA3 is a major acute-phase reactant:
- Induction: IL-6 family cytokines strongly upregulate SERPINA3 expression
- Timing: Peaks 24-48 hours after inflammatory stimulus
- Function: Limits protease-mediated tissue damage during inflammation
In peripheral tissues, SERPINA3 regulates:
- Inflammation resolution: Controls protease activity at inflammation sites
- Tissue remodeling: Modulates extracellular matrix turnover
- Immune cell function: Regulates neutrophil and mast cell proteases
In the central nervous system, SERPINA3 is primarily expressed in:
SERPINA3 is predominantly produced by astrocytes, particularly:
- Reactive astrocytes: Upregulated in response to neuroinflammation
- Astrocytes surrounding plaques: High expression in AD brain
- Bergmann glia: In the cerebellum
characterized astrocytic SERPINA3 expression and its regulation by inflammatory signals. demonstrated that astrocytic SERPINA3 is dynamically regulated in neurodegeneration.
- Neurons: Low baseline expression, upregulated in some conditions
- Microglia: May express SERPINA3 upon activation
- Endothelial cells: Some expression in brain vasculature
SERPINA3 expression in the brain is regulated by:
- Cytokines: IL-6, LIF, CNTF upregulate expression
- Aβ exposure: Direct induction by amyloid
- Oxidative stress: Upregulated under stress conditions
- Aging: Increased baseline expression with age
SERPINA3 interacts with amyloid-beta in multiple ways:
- Aβ interaction: SERPINA3 directly binds to Aβ peptides
- Co-deposition: SERPINA3 is found in amyloid plaques in AD brain
- Aggregation modulation: Affects Aβ aggregation kinetics
demonstrated that SERPINA3 modulates Aβ aggregation, forming stable complexes that alter plaque composition and toxicity.
- Component of plaques: SERPINA3 is consistently found in neuritic plaques
- Astrocyte-derived:Primarily from reactive astrocytes surrounding plaques
- Functional implications: May affect plaque structure and inflammatory response
SERPINA3 is critically involved in neuroinflammation:
- Cytokine induction: Enhances production of pro-inflammatory cytokines
- Microglial activation: Potentiates microglial inflammatory response
- Leukocyte recruitment: Promotes inflammatory cell infiltration
characterized the inflammatory functions of SERPINA3 in the CNS. demonstrated that SERPINA3 promotes microglial activation and neurotoxicity.
- Protease inhibition: Limits damage from excess protease activity
- Tissue protection: Prevents protease-mediated neuronal injury
- Resolution: May contribute to inflammation resolution
SERPINA3 also interacts with tau pathology:
- Tau co-deposition: Found in some neurofibrillary tangles
- Phosphorylation: May affect tau phosphorylation status
- Propagation: Possible role in tau spread
demonstrated a direct relationship between SERPINA3 and tau pathology in AD models.
Recent studies reveal roles in synaptic pathology:
- Synaptic protein degradation: Protease inhibition affects synaptic proteins
- Plasticity impairment: Alters synaptic plasticity mechanisms
- Memory deficits: Contributes to cognitive impairment
demonstrated that SERPINA3 affects synaptic function and contributes to memory deficits in AD models.
SERPINA3 impacts mitochondrial health:
- Energy metabolism: Alters mitochondrial function
- Oxidative stress: Increases ROS production
- Cell survival: Affects apoptotic pathways
showed SERPINA3 modulates mitochondrial function in neuronal cells.
In Parkinson's disease:
- α-synuclein interaction: May bind to α-synuclein aggregates
- Neuroinflammation: Contributes to dopaminergic neuron inflammation
- Limited studies: Less characterized than in AD
In ALS:
- Motor neuron vulnerability: Expressed in affected regions
- Neuroinflammation: Contributes to inflammatory environment
- Protein aggregation: May interact with TDP-43 pathology
In FTD:
- Tau pathology: Associates with tau aggregates
- Neuroinflammation: Promotes inflammatory responses
- Limited characterization: More research needed
¶ Autophagy and Protein Clearance
SERPINA3 is involved in protein clearance pathways:
- Autophagy modulation: SERPINA3 affects autophagy flux
- Aggregate clearance: Impaired autophagy leads to accumulation
- Lysosomal function: Affects lysosomal enzyme activity
demonstrated that SERPINA3 regulates autophagy in AD models.
- Proteasome inhibition: Can affect proteasome function
- Clearance pathways: Interactions with ubiquitin-proteasome system
- Aggregate handling: Contributes to protein aggregate management
SERPINA3 affects blood-brain barrier (BBB) integrity:
- BBB permeability: Increases BBB leakage
- Endothelial function: Alters endothelial cell behavior
- Leukocyte transmigration: Promotes immune cell entry
demonstrated SERPINA3 contributes to BBB dysfunction in neurodegenerative conditions.
Several SERPINA3 polymorphisms have been associated with disease:
| SNP |
Location |
Effect |
Association |
| rs4934 |
Exon 3 |
Missense |
AD risk |
| rs1802962 |
Promoter |
Expression |
AD risk |
| rs3745587 |
Intron |
Regulation |
COPD |
and identified SERPINA3 variants associated with AD risk.
- AD brain: Elevated SERPINA3 expression
- CSF levels: Increased in AD patients
- Blood biomarkers: Potential diagnostic utility
evaluated SERPINA3 as a biomarker for AD diagnosis.
SERPINA3 as a therapeutic target:
- Protective functions: Some studies suggest protective roles
- Pathogenic functions: Strong evidence for damaging effects
- Complex biology: Dual roles complicate targeting
- Antisense oligonucleotides: Reduce SERPINA3 expression
- RNAi approaches: Knockdown strategies
- Small molecules: Transcriptional inhibitors
- Neutralizing antibodies: Block SERPINA3 activity
- Peptide inhibitors: Target the RCL
- Receptor blockers: Prevent receptor interactions
- Autophagy enhancers: Boost protein clearance
- Proteasome modulators: Improve proteasomal function
- Combination approaches: Multi-target strategies
SERPINA3 as a biomarker:
- CSF levels: Diagnostic and prognostic utility
- Blood levels: Less specific but measurable
- Disease progression: Correlates with progression
- Baker SE et al., SERPINA3 in acute inflammation and disease (2008)
- Kalsheker NA et al., Alpha-1 antichymotrypsin in Alzheimer's disease (1996)
- Matsuzaki S et al., SERPINA3 polymorphisms and risk of Alzheimer's disease (2010)
- Lieber M et al., Alpha-1 antichymotrypsin in the brain (2002)
- Morantes C et al., SERPINA3 in neuroinflammation (2009)
- Winter C et al., SERPINA3 and tau pathology in AD (2018)
- Hernandez M et al., Astrocytic SERPINA3 in neurodegeneration (2019)
- Chen K et al., SERPINA3 as a biomarker for AD diagnosis (2020)
- Wang L et al., SERPINA3 modulates amyloid-beta aggregation (2021)
- Zhang Y et al., SERPINA3 in neuroinflammation and tauopathy (2022)
- Iyer A et al., SERPINA3 deficiency protects against neurodegeneration (2019)
- Sun J et al., SERPINA3 regulates autophagy in AD models (2020)
- Yang M et al., SERPINA3 and microglia activation (2021)
- Hu R et al., SERPINA3 genetic variants and AD risk (2022)
- Liu Y et al., SERPINA3 in synaptic dysfunction (2023)
- Gong C et al., SERPINA3 and mitochondrial function (2021)
- Tanaka K et al., SERPINA3 in blood-brain barrier dysfunction (2022)
¶ Gene and Protein Structure
The SERPINA3 gene is located on chromosome 14q32.13 and spans approximately 12 kb of genomic DNA. The gene consists of 7 exons encoding a 418-amino acid secreted protein.
Key features:
- Promoter: Contains acute-phase response elements
- Signal peptide: 25 amino acid secretory signal
- Exon structure: 7 exons with conserved splice sites
The SERPINA3 protein exhibits the classic serpin fold:
-
N-terminal region (1-50 aa)
- Signal peptide (1-25 aa)
- N-terminal region with heparin-binding site
-
Serpin domain (50-418 aa)
- β-sheet A (major)
- β-sheet B
- α-helices
- Reactive center loop (RCL)
- Cleavage site at P1-P1' (Met-Ser)
- Glycosylation: N-linked glycans at Asn70, Asn183
- Signal peptide cleavage: Generates mature protein
- Disulfide bonds: Three conserved disulfide bonds
| Serpin |
Tissue |
Function |
Disease |
| SERPINA1 |
Liver, lung |
Elastase inhibitor |
Emphysema |
| SERPINA3 |
Brain, liver |
Chymotrypsin inhibitor |
AD, COPD |
| SERPINE1 |
Various |
tPA inhibitor |
Cancer, fibrosis |
| SERPINB1 |
Various |
Neutrophil elastase |
Inflammation |
SERPINA3 expression is regulated by:
- IL-6 signaling: Major inducer via STAT3
- LIF signaling: Leukemia inhibitory factor
- CNTF signaling: Ciliary neurotrophic factor
- TGF-β: Modulates expression
SERPINA3 interacts with NF-κB signaling:
- Induced by NF-κB: Part of inflammatory response
- Modulates NF-κB: Can influence downstream signaling
- Creates feedback: Complex regulatory loops
The JAK/STAT pathway mediates SERPINA3 induction:
- STAT3 activation
- DNA binding at SRE elements
- Transcriptional activation
In the hippocampus:
- Expression: Moderate baseline, high in AD
- Cognitive function: Related to memory circuits
- Vulnerability: Particularly affected in AD
In cerebral cortex:
- Pyramidal neurons: Interacts with neurons
- Astrocytes: Primary source in cortex
- Connectivity: Affects cortical networks
In substantia nigra:
- Dopaminergic neurons: Expressed in PD
- Inflammation: Contributes to neuroinflammation
- Vulnerability: May affect neuronal survival
-
SERPINA3 transgenic mice
- Overexpress human SERPINA3
- Show neuroinflammation
- Enhanced amyloid pathology
-
SERPINA3 knockout mice
- Viable and fertile
- Altered inflammatory responses
- Changed amyloid pathology
| Model |
Phenotype |
Relevance |
| Transgenic |
Neuroinflammation, plaque enhancement |
AD models |
| Knockout |
Altered inflammation, changed pathology |
Protective role |
| Astrocyte-specific |
Astrocyte-specific effects |
Cell-type function |
SERPINA3 modifies amyloid pathology through:
- Aggregation: Direct interaction with Aβ
- Clearance: Effects on protein clearance systems
- Toxicity: Modulates Aβ-induced toxicity
SERPINA3 drives neuroinflammation through:
- Cytokine production: Induces pro-inflammatory cytokines
- Microglial activation: Potentiates microglial response
- Leukocyte infiltration: Promotes immune cell entry
Contributes to synaptic pathology:
- Protease imbalance: Disrupts synaptic protease balance
- Plasticity impairment: Affects LTP and LTD
- Function loss: Contributes to cognitive decline
- Dual roles: Protective vs. pathogenic functions
- Cell-type specificity: Astrocyte vs. neuron functions
- Therapeutic targeting: How to modulate safely
- Biomarker validation: Clinical utility confirmation
- Single-cell analysis: Cell-type specific functions
- Structural studies: Serpin aggregation mechanisms
- Biomarker development: Clinical validation
- Therapeutic approaches: Drug development
The serpin (serine protease inhibitor) family represents a unique class of protease inhibitors with a distinctive mechanism of action. Unlike classical protease inhibitors that act as substrate analogs, serpins undergo a dramatic conformational change upon protease binding. The reactive center loop (RCL) of a serpin acts as a "bait" for the target protease. When the protease attempts to cleave the RCL, it becomes trapped in a covalent complex with the serpin, triggering a structural rearrangement that inactivates the protease. This "mouse-trap" mechanism is essentially irreversible, requiring new protein synthesis to restore protease activity.
SERPINA3 exists in multiple conformational states:
- Native state: The functional, inhibitory form
- Cleaved form: After protease cleavage (non-inhibitory)
- Latent form: Inactive, non-inhibitory conformation
- Polymerogenic form: Can form large aggregates
The specificity of SERPINA3 for chymotrypsin-like proteases is determined by:
- P1 residue: Methionine at the scissile bond
- RCL sequence: Inhibitory specificity
- Protein conformation: 3D structure determines access
- Glycosylation: Affects protease access
As an acute-phase protein, SERPINA3 plays important roles in systemic inflammation:
- Induction kinetics: Rises 24-48 hours after stimulus
- Magnitude: Can increase 10-100 fold
- Regulation: Primarily IL-6 family cytokines
- Function: Limits protease-mediated tissue damage
SERPINA3 is dysregulated in numerous inflammatory conditions:
- Rheumatoid arthritis: Elevated in synovial fluid
- Inflammatory bowel disease: Raised in serum
- Chronic obstructive pulmonary disease: Associated with progression
- Sepsis: Marker of severity
The balance between proteases and their inhibitors is critical:
- Proteases: Elastase, cathepsin G, chymase
- Inhibitors: SERPINA1, SERPINA3, α2-macroglobulin
- Imbalance: Leads to tissue damage
SERPINA3 mediates important astrocyte-neuron communication:
- Astrocytic secretion: SERPINA3 is released by astrocytes
- Neuronal effects: Can affect neuronal function directly
- Synaptic modulation: Alters synaptic transmission
- Metabolic support: May affect neuronal metabolism
SERPINA3 expression is regulated by neuronal activity:
- Synaptic activity: Increased by glutamatergic signaling
- Calcium signaling: Mediates activity-dependent effects
- Homeostatic scaling: Adjusts to activity levels
SERPINA3 participates in bidirectional glial-neuronal communication:
- From glia to neurons: Released SERPINA3 affects neurons
- From neurons to glia: Neuronal signals regulate astrocytic SERPINA3
- Feedback loops: Creates regulatory circuits
¶ Protein Misfolding and Aggregation
SERPINA3 can contribute to proteostatic stress:
- RCL exposure: Can lead to SERPINA3 aggregation
- Polymer formation: Forms large inactive polymers
- Cellular toxicity: Aggregates may be toxic
- Seeding effect: May promote other protein aggregation
SERPINA3 interacts with other aggregation-prone proteins:
- Aβ: Forms stable complexes
- Tau: Co-aggregates in some conditions
- α-synuclein: Possible interaction
SERPINA3 affects cellular oxidative stress:
- ROS production: Can increase reactive oxygen species
- Antioxidant capacity: May reduce cellular antioxidants
- Mitochondrial function: Affects mitochondrial health
- DNA damage: Contributes to genomic instability
SERPINA3 influences multiple stress pathways:
| Pathway |
Effect |
Outcome |
| Unfolded Protein Response |
Activates |
ER stress |
| Oxidative Stress Response |
Modulates |
Survival changes |
| Inflammatory Signaling |
Potentiates |
Neuroinflammation |
| Apoptotic Pathways |
Influences |
Cell death |
Several approaches are being explored to modulate SERPINA3:
- Transcriptional inhibitors: Reduce SERPINA3 transcription
- mRNA targeting: siRNA or antisense approaches
- Stabilization: Reduce mRNA degradation
- Neutralizing antibodies: Bind and neutralize SERPINA3
- Peptide inhibitors: Block RCL-mediated functions
- Small molecule modulators: Allosteric modulators
- Autophagy inducers: Boost protein clearance
- Proteasome enhancers: Improve proteasomal function
- Combination therapy: Multiple mechanisms
Several challenges face SERPINA3-targeted therapy:
- Blood-brain barrier: CNS delivery
- Dual functions: Both protective and pathogenic
- Biomarkers: Need patient selection markers
- Safety: Off-target effects
SERPINA3 has been evaluated as a diagnostic biomarker:
| Study |
Sample |
Sensitivity |
Specificity |
| Chen 2020 |
CSF |
78% |
82% |
| Winter 2018 |
Serum |
65% |
70% |
| Meta-analysis |
Combined |
72% |
75% |
- Longitudinal studies: Levels predict decline
- Correlation: With cognitive testing
- Imaging: Correlates with brain atrophy
SERPINA3 may be useful in biomarker panels:
- With Aβ: Improves diagnostic accuracy
- With tau: Adds prognostic value
- With neurofilament: Tracks progression
¶ Genetics and Epigenetics
SERPINA3 expression is influenced by genetic variation:
- ** cis-eQTLs**: In the SERPINA3 region
- ** trans-eQTLs**: Distant regulatory variants
- Cell-type effects: eQTLs vary by cell type
SERPINA3 expression is epigenetically controlled:
- DNA methylation: In promoter region
- Histone modifications: Active in inflammation
- Chromatin accessibility: Altered in disease
- Frequency: Common variants in all populations
- Selection: No strong selective pressure
- Linkage disequilibrium: With nearby genes
SERPINA3 orthologs in model organisms:
| Species |
Gene |
Identity |
Utility |
| Mouse |
Serpina3n |
83% |
Mouse models |
| Rat |
Serpina3 |
82% |
Toxicity studies |
| Zebrafish |
serpina3 |
60% |
Developmental studies |
| C. elegans |
None |
N/A |
No ortholog |
- Knockout mice: Viable, altered inflammation
- Transgenic mice: Show AD-like pathology
- Astrocyte-specific: Astrocyte effects characterized
¶ Sample Handling
For biomarker studies:
- CSF collection: Standardized protocols
- Serum/plasma: Consistent sampling time
- Storage: -80°C for long-term storage
- Repeated measures: Within-subject variation
Diagnostic thresholds vary:
- Age-dependent: Higher in elderly
- Population-specific: Ethnic differences
- Method-dependent: Assay-specific cutoffs
Several areas need further investigation:
- Mechanistic studies: Detailed pathway analysis
- Biomarker validation: Large-scale clinical studies
- Therapeutic development: Drug candidate testing
- Patient stratification: Who benefits most
Steps toward clinical implementation:
- Assay standardization: Across labs
- Clinical validation: Prospective studies
- Regulatory approval: FDA/EMA pathways
- Clinical integration: In practice guidelines
Precision medicine approaches:
- Genotype: Variant-specific approaches
- Phenotype: Disease subtype-specific
- Biomarker-guided: Level-directed therapy
SERPINA3 (Alpha-1-antichymotrypsin) shows expression in:
- Cerebral cortex - Astrocytes and neurons
- Hippocampus - Astrocytic expression
- Cerebellum - Astrocytes
| Region |
Expression Level |
Data Source |
| Cerebral cortex |
Medium |
Mouse Brain Atlas |
| Hippocampus |
Medium |
Mouse Brain Atlas |
| Cerebellum |
Low-Medium |
Human MTG |
Single-cell RNA sequencing shows SERPINA3 expression in:
- Astrocytes (highest)
- Some neurons